{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:44:37Z","timestamp":1788878677298,"version":"build-2803163510"},"reference-count":16,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["N01\u2010AI\u201030016"],"award-info":[{"award-number":["N01\u2010AI\u201030016"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Availability of a safe smallpox vaccine may be necessary under certain circumstances. Use of the old life virus vaccine was associated with serious adverse events, particularly in the setting of atopic eczema (AE) and immunodeficiency. Modified virus Ankara (<jats:styled-content style=\"fixed-case\">MVA<\/jats:styled-content>)\u2010<jats:styled-content style=\"fixed-case\">BN<\/jats:styled-content>, a highly attenuated strain of vaccinia virus, was developed for vaccination with improved safety profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A phase 1 study was conducted in 60 subjects without history of smallpox vaccination to gain experience with smallpox vaccination using this strain in healthy and atopic subjects. Healthy subjects, subjects with a history of <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>, subjects with mild active <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> and subjects with mild allergic rhinitis without <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> were equally allocated into four groups. <jats:styled-content style=\"fixed-case\">MVA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">BN<\/jats:styled-content> was injected s.c. in a dose of 10<jats:sup>8<\/jats:sup> <jats:styled-content style=\"fixed-case\">TCID<\/jats:styled-content><jats:sub>50<\/jats:sub> twice in a 4\u2010week interval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No serious or unexpected adverse reactions were reported. All subjects experienced mild to moderate pain and redness at the injection site. Dermatologic examinations did not reveal any unfavourable reactions to the study medication, particularly no sign or exacerbation of eczema for as long as 196 days. All subjects seroconverted after two vaccinations and no significant difference in antibody titres between the four different groups was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A good safety profile of the <jats:styled-content style=\"fixed-case\">MVA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">BN<\/jats:styled-content> vaccine was shown. The absence of adverse events in subjects with atopic disorders appears promising for the development of a safe smallpox vaccine for patients with <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> or other atopic diseases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.13797","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T03:43:13Z","timestamp":1467258193000},"page":"1971-1977","source":"Crossref","is-referenced-by-count":21,"title":["Long\u2010term safety of replication\u2010defective smallpox vaccine (MVA\u2010BN) in atopic eczema and allergic rhinitis"],"prefix":"10.1111","volume":"30","author":[{"given":"U.","family":"Darsow","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy Biederstein Technical University of Munich (TUM) and ZAUM \u2013 Center of Allergy and Environment Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sbornik","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Biederstein Technical University of Munich (TUM) and ZAUM \u2013 Center of Allergy and Environment Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rombold","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Biederstein Technical University of Munich (TUM) and ZAUM \u2013 Center of Allergy and Environment Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Katzer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Biederstein Technical University of Munich (TUM) and ZAUM \u2013 Center of Allergy and Environment Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"von Sonnenburg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine Ludwig\u2010Maximilian\u2010University Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Behrendt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Biederstein Technical University of Munich (TUM) and ZAUM \u2013 Center of Allergy and Environment Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ring","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Biederstein Technical University of Munich (TUM) and ZAUM \u2013 Center of Allergy and Environment Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Geneva December 1979. World Health Organization Geneva 1980."},{"key":"e_1_2_6_3_1","volume-title":"Smallpox and its Eradication","author":"Fenner H","year":"1988"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.128052"},{"key":"e_1_2_6_5_1","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"Kemper AR","year":"2002","journal-title":"Eff Clin Pract"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1108143"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/421266"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.09.037"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.06.042"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.11.022"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000245677"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin JMRG","year":"1980","journal-title":"Acta Derm Venerol"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2005.00040.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-29856-8"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.08.004"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.3.1763"},{"key":"e_1_2_6_17_1","first-page":"5696","article-title":"Safety and immunogenicity of the third generation smallpox vaccine IMVAMUNE\u00ae (MVA\u2010BN\u00ae) in atopic dermatitis patients","volume":"32","author":"Sonnenburg F","year":"2014","journal-title":"Vaccine"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13797","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13797","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:24:02Z","timestamp":1695572642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/jdv.13797"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13797","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,29]]}}}